Evidence map›Paper›PMID 38312483›Full record

ArticlePolymers for advanced technologies2023

NOVEL HIGH-STRENGTH POLYESTER COMPOSITE SCAFFOLDS FOR BONE REGENERATION.

Sara Katebifar, Michael Arul, Sama Abdulmalik, Xiaojun Yu, Joseph F Alderete, Sangamesh G Kumbar

Abstract read
In one paragraph

Article in Polymers for advanced technologies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Alveolar Bone Regeneration: Smart Biomaterials and Physical Stimulation.Journal of biomedical materials research. Part B, Applied biomaterials · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara KatebifarDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, 06030, USA.
Michael ArulDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, 06030, USA.
Sama AbdulmalikDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, 06030, USA.
Xiaojun YuDepartment of Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, 07030, USA.
Joseph F AldereteDepartments of Orthopedic Surgery, Brooke Army Medical Center, Joint Base San Antonio, Texas.
Sangamesh G KumbarDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, 06030, USA.

Funding

Targeting PHLPP to treat interval disc degeneration using surgical and drug delivery methodsR01AR078908 · NIAMS · EMORY UNIVERSITY · PI Svenja Illien-Junger · 2022 to 2026
$1.9M
Biodegradable Matrices for Bone HealingR01EB020640 · NIBIB · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KUMBAR, SANGAMESH GURAPPA, YU, XIAOJUN · 2017 to 2020
$1.6M
Polysaccharide putty formulations for tissue regenerationR01EB034202 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Sangamesh Gurappa Kumbar · 2023 to 2026
$1.5M
Biodegradable Matrices with Structural and Physical Cues for Interface EngineeringR01EB030060 · NIBIB · UNIVERSITY OF CONNECTICUT STORRS · PI NUKAVARAPU, SYAM · 2020 to 2024
$1.4M
Supplement to Support the Acquisition of a High-Precision 3D PrinterR01NS134604 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Sangamesh Gurappa Kumbar · 2024 to 2026
$1.3M
Engineered Matrices with Electrical and Chemical Stimulation for Peripheral Nerve RepairR56NS122753 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KUMBAR, SANGAMESH GURAPPA · 2022 to 2022
$410k
NIAMS NIH HHS R01 AR078908NIBIB NIH HHS R01 EB020640NIBIB NIH HHS R01 EB030060NIBIB NIH HHS R01 EB034202NINDS NIH HHS R01 NS134604NINDS NIH HHS R56 NS122753
6 · The paper itself

Abstract

Repair of critical sized bone defects, particularly in load-bearing areas, is a major clinical problem that requires surgical intervention and implantation of biological or engineered grafts. For load-bearing sites, it is essential to use engineered grafts that have both sufficient mechanical strength and appropriate pore properties to support bone repair and tissue regeneration. Unfortunately, the mechanical properties of such grafts are often compromised due to the creation of pores required to facilitate tissue ingrowth following implantation. To overcome the limitations associated with porous scaffolds and their reduced mechanical strength, we have developed a methodology for creating a solid structure that retains its bulk mechanical properties while also evolving into a porous structure in a biological environment through degradation and erosion. In this study, we utilized polyesters that have been approved by the FDA, including poly (lactic acid) (PLA), poly(glycolic acid) (PGA), their copolymer PLGA (PLGA, with a ratio of 85:15 and 50:50 of PLA:PGA), and poly(caprolactone) (PCL). These polymers and their ceramic composites with tricalcium phosphate (TCP) were compression molded into solid forms, which exhibited mechanical properties with compressive modulus as high as 2745 ± 364 MPa within the range of human trabecular bone and in the lower range of human cortical bone. The use of fast-degrading PLGA (50:50) and PGA as porogens allowed the formation of pores within the solid structures due to their degradation, and the TCP acts as a buffering agent to neutralize their acidic degradation byproducts. These scaffolds facilitated the growth of new blood vessels and tissue ingrowth in a subcutaneous implantation model. In addition, in a rat critical-sized mandibular bone defects these scaffolds supported bone growth with 70% of new bone volume fraction. Furthermore, the extent of bone regeneration was found to be higher for the scaffolds with bone morphogenic proteins (BMP2), indicating their suitability for bone repair and regeneration.

Indexed as

Aliphatic polyestersBone tissue engineeringCalcium phosphateDegradationLoad bearing scaffoldsMechanical stabilityPorous structure

Identifiers

PMID38312483
PMCPMC10836609

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.